The company is expanding the site’s sterile fill-finish capabilities while sunsetting traditional batch, solid dose production and adopting continuous manufacturing.
The investment at the CDMO’s sites in Aarau and Neuland, Switzerland will support the production of a drug linker for a commercial antibody-drug conjugate.
The company is scaling its logistics infrastructure at sites in Tennessee and the Netherlands to meet growing demand for injectable and biologic drug products.
